Open Journal Systems

Research progress in bladder cancer

VIEWS - 62 (Abstract) 36 (PDF)

Chong Li, Xue Tan, Fangjing Fan, Xu Zhang, Zhao Yang, Meiqing Wang

Abstract

Bladder cancer refers to malignant tumors that originate in the bladder mucosa. Globally, bladder cancer is the ninth most common malignant tumor and the second most common urinary tumor. Recently, the search for highly sensitive, specific, non-invasive, convenient, quick, and economical bladder cancer diagnosis and follow-up methods becomes a research challenge in the fields of basic medicine, oncology, and urology. This article covers the current status of national and international research on the diagnosis and treatment of bladder cancer, as well as the forefront achievement from our team and international peers in basic and translational medicine research on bladder cancer. As translational medicine is the only way to achieve precision medicine, there are unprecedented opportunities in the fields of bladder cancer research and translational medical research.

Keywords

bladder cancer; diagnosis; treatment; translational medicine; precision medicine

Full Text:

PDF

References

Torre LA, Bray F, Siegel RL, et al., 2015, Global Cancer Statistics, 2012. CA Cancer J Clin, 65(2):87-108.

Antoni S, Ferlay J, Soerjomataram I, et al., 2016, Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol, 71:96-108. DOI 10.1016/j. eururo.2016.06.010.

Sujun H, Sizhi Z, Wanqing C, et al., 2013, Analysis of the Current Status and Epidemic Trends of Bladder Cancer in China. Cancer Prog, 11(1):89-95.

Wanqing C, Rongshou Z, Sizhi Z, et al., 2016, Analysis of the Incidence and Mortality of Malignant Tumors in China in 2012. Chin J Tumor, 25(1):1-8.

Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al., 2007, Epidemiology of Urinary Bladder Cancer: From Tumor Development to Patient’s Death. World J Urol, 25(3):285-95. DOI 10.1007/s00345-007-0168-5.

Zhang H, Guo Y, Song Y, et al., 2016, Long Noncoding RNA GAS5 Inhibits Malignant Proliferation and Chemotherapy Resistance to Doxorubicin in Bladder Transitional Cell Carcinoma. Cancer Chemother Pharmacol, 79(1):49-55. DOI 10.1007/s00280-016-3194-4.

Kamat AM, Hahn NM, Efstathiou JA, et al., 2016, Bladder Cancer. Lancet, 388(10061):2796-810. DOI 10.1016/ s0140-6736(16)30512-8.

Babjuk M, Bohle A, Burger M, et al., 2016, EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol, 71(3):447-61. DOI 10.1016/j.eururo.2016.11.030.

Bi L, Huang H, Fan X, et al., 2014, Extended vs Non-extended Pelvic Lymph Node Dissection and their Influence on Recurrence-free Survival in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-analysis of Comparative Studies. BJU Int, 113(5b):E39-E48. DOI 10.1111/bju.12371.

Zargar H, Espiritu PN, Fairey AS, et al., 2015, Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol, 67(2):241-49.

Galsky MD, Pal SK, Chowdhury S, et al., 2015, Comparative Effectiveness of Gemcitabine Plus Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Cancer, 121(15):2586-93. DOI 10.1002/cncr.29387.

Grossman HB, Natale RB, Tangen CM, et al., Neoadjuvant Chemotherapy Plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. N Engl J Med, 349(9):859-66. DOI 10.1056/nejmoa022148.

Mankoff SP, Brander C, Ferrone S, et al., 2004, Lost in Translation: Obstacles to Translational Medicine. J Transl Med, 2(1):14.

Xia X, Jinming Z, Hong Z, et al., 2016, Practice and Thinking of Translational Medicine from the Perspective of Research-oriented Medicine. Chin J Hosp Manag 32(1):19-21.

Li C, Du Y, Yang Z, et al., 2016, GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-renewal and Tumor-initiating Capacity of Bladder Cancer Stem Cells. Cancer Res, 76(5):1273-83. DOI 10.1158/0008-5472.can-15-2309.

Li C, Yang Z, Du Y, et al., 2014, BCMab1, a Monoclonal Antibody Against Aberrantly Glycosylated Integrin alpha3beta1, has Potent Antitumor Activity of Bladder Cancer in vivo. Clin Cancer Res, 20(15):4001-13. DOI 10.1158/1078-0432.ccr-13-3397.

Yang Z, Li C, Liu H, et al., 2016, Single-cell Sequencing Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of Human Bladder Cancer Stem Cells. Eur Urol, 71(1):8-12. DOI 10.1016/j.eururo.2016.06.025.

Yang Z, Wu S, Cai Z, et al., 2016, Reply from Authors Re: Xue-Ru Wu. Attention to Detail by Single-cell Sequencing. Eur Urol, 71(1):15-6. DOI 10.1016/j.eururo.2016.11.003.

DOI: http://dx.doi.org/10.18063/c+.v1i2.236